Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04440943 · ClinicalTrials.gov registry record · Phase 1
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04440943 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT04440943, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Interventions
- DRUG CDX-527
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2023-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04440943
The ClinicalTrials.gov registry entry for NCT04440943 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDX-527 is the first listed.
NCT04440943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04440943 about?
NCT04440943 is a clinical study titled "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies". This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
What is the current status of trial NCT04440943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2020-08-04. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT04440943?
The interventions under investigation include: CDX-527 (DRUG).
Who is sponsoring clinical trial NCT04440943?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.